TargetBeta
IL6R
interleukin 6 receptor · also CD126, IL-6R, IL-1Ra, IL6RA · CD molecules
2 programs in company-led studies act on IL6R, from 2 companies: 0 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| tocilizumabrule | Hoffmann-La Roche | phase 4 | 1305 running | – | NCIt |
| sarilumabrule | Sanofi | phase 4 | 273 running | – | NCIt |
Conditions their studies are in
- Arthritis, Juvenile, 2 programs
- Arthritis, Rheumatoid, 2 programs
- Coronavirus Infections, 1 program
- COVID-19, 1 program
- Giant Cell Arteritis, 1 program
- Polymyalgia Rheumatica, 1 program
- Scleroderma, Systemic, 1 program
- Spondylitis, Ankylosing, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jul 30, 2027tocilizumab · Hoffmann-La Roche · phase 4 · NCT04524871
- Mar 1, 2028sarilumab · Sanofi · phase 4 · NCT02991469
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.